Aaron Cowen’s Genmab GMAB Stock Holding History

Aaron Cowen’s Portfolio GMAB Stock Details GMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-5,210	Closed	-$221K	–	103
2022 Q4	$221K	Buy	+5,210	New	+$215K	0.01%	85

Other funds holding GMAB

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

1832 Asset Management Toronto, Ontario, Canada $199B AUM 37.98% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Aaron Cowen's GMAB Position: Q1 2023 in Review

Aaron Cowen sold out of Genmab (GMAB) in Q1 2023, closing a stake of 5,210 shares — an estimated $221K sold.

Aaron Cowen first reported a position in GMAB in Q4 2022 and held it in 1 quarter. The position peaked at $221K in Q4 2022. 217 funds tracked by Wall St. Rank hold GMAB as of Q1 2023.

Aaron Cowen reported no remaining Genmab position as of Q1 2023 after selling out during the quarter.
Aaron Cowen sold 5,210 Genmab shares in Q1 2023, an estimated $221K.
Aaron Cowen first reported a position in Genmab in Q4 2022 and held it in 1 quarter.
Aaron Cowen's Genmab position peaked at $221K in Q4 2022.
217 funds tracked by Wall St. Rank held Genmab as of Q1 2023.

Based on Suvretta Capital Management's 13F filing for Q1 2023, filed 15 May 2023.